Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.65 |
| ▸ | KDR | P35968 | 12/20 | 0.65 |
| ▸ | FLT4 | P35916 | 7/20 | 0.65 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.65 |
| ▸ | FLT1 | P17948 | 3/20 | 0.65 |
| ▸ | SRC | P12931 | 4/20 | 0.63 |
| ▸ | AURKA | O14965 | 8/20 | 0.60 |
| ▸ | TEK | Q02763 | 8/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.58 |
| ▸ | RET | P07949 | 1/20 | 0.57 |
| ▸ | KIF5B | P33176 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3673831 | 0.94 | KDR (0.64) | EGFRKDRFLT4FGFR1FLT1 | |
| SCHEMBL3673786 | 0.93 | KDR (0.63) | EGFRKDRFLT4FGFR1FLT1 | |
| SCHEMBL3675469 | 0.93 | SRC (0.73) | EGFRKDRFLT4FGFR1FLT1 | |
| SCHEMBL3669672 | 0.92 | KDR (0.59) | EGFRKDRFLT4FGFR1FLT1 | |
| SCHEMBL3679331 | 0.87 | KDR (0.65) | EGFRKDRFLT4FGFR1FLT1 | |
| SCHEMBL3669683 | 0.85 | EGFR (0.69) | EGFRKDRFLT4FGFR1FLT1 | |
| SCHEMBL3679436 | 0.83 | KDR (0.88) | EGFRKDRFLT4FGFR1FLT1 | |
| SCHEMBL3679327 | 0.82 | SRC (0.86) | EGFRKDRFLT4FGFR1FLT1 | |
| SCHEMBL3680124 | 0.81 | KDR (0.64) | EGFRKDRFLT4FGFR1FLT1 | |
| SCHEMBL3668100 | 0.80 | KDR (0.71) | EGFRKDRFLT4FGFR1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939866-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | claimed |
| US-20040044015-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | US | claimed |
| EP-1326860-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-07-16 | — | — | EP | claimed |
| WO-2002030926-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | claimed |
| EP-1562612-B1 | COMBINATION PRODUCT OF INHIBITOR OF THE SRC FAMILY OF NON-RECEPTOR TYROSINE KINASES AND GEMCITABINE FOR USE IN THE TREATMENT OR PROPHLAXIX OF PANCREATIC CANCER | ASTRAZENECA AB (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20060142297-A1 | Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | US | disclosed |
| US-6939866-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | disclosed |
| EP-1562612-A1 | COMBINATION PRODUCT OF INHIBITOR OF THE SRC FAMILY OF NON-RECEPTOR TYROSINE KINASES AND GEMCITABINE | Astrazeneca AB (SE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004087120-A2 | USE OF QUINAZOLINE DERIVATIVES WITH SRC KINASE INHIBITORY ACTIVITY FOR THE TREATMENT OF HYPERTENSION | ASTRAZENECA AB (SE) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004043472-A1 | COMBINATION PRODUCT OF INHIBITOR OF THE SRC FAMILY OF NON-RECEPTOR TYROSINE KINASES AND GEMCITABINE | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | WO | disclosed |
| US-20040044015-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-03-04 | — | — | US | disclosed |
| EP-1326860-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030926-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044015-A1 | Quinazoline derivatives | NQO2, NRAS, TOP1 | EGFR 1832/4885KDR 2216/4885FLT4 1148/4885 |
| US-20060142297-A1 | Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine | SRC, PTPN4, PTPN1 | EGFR 155/4885KDR 825/4885FLT4 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.